搜索公司,投資者……

階段

收購了 |收購

總了

60美元

約好的開始遺傳學

良好的開端遺傳學提供偏見載體篩查婦產科和ACMG推薦的障礙,以及一個擴展的德係猶太人測試菜單。公司的測試菜單設計輸入從一個專家小組的生殖健康醫生和遺傳輔導員來自全國各地。好的開始設計了其測試菜單容易遵守社會準則。公司的新一代測序(上天)平台是一個具有成本效益的平台訪問常規基因載體的篩選。利用門店,好的開始將評估病人的DNA樣本檢測常見和小說與隱性遺傳疾病相關的致病突變,因此提供了一個深入的分析遠遠超出當前目標突變分析平台。

總部的位置

普特南大街237號

劍橋,馬薩諸塞州,02139年,

美國

866-765-0845

188bet游戏
尋找一個腿上有競爭力的,客戶技術見解?
188bet游戏CB的見解將信心和清晰你最戰略決策。
看看。加入一個演示。
加入一個演示
信任由世界最聰明的公司:
  • 預測新興趨勢
  • 看到競爭對手的劇本
  • 莖精明的投資者
  • 確定明天的挑戰者
  • 現貨產業增長
  • 殺了分析師的數據工作
讓我們看看我們如何能幫助你!
微軟 沃爾瑪 富國銀行(Wells Fargo)
你一次點擊從最全麵、無與倫比的分析師專長技術,深入的私人公司數據和一個平台,將它們放在一起。
現在點擊。加入一個現場演示
加入一個演示

遺傳學專家集合包含良好的開端

專家集合是analyst-curated列表,突出了公司你需要知道的最重要的技術空間。

良好的開端遺傳學中包含5專家集合,包括醫療設備

醫療設備

8633件

公司發展醫療器械(每IMDRF的“醫療器械”的定義)。包括軟件、lab-developed測試(LDTs)和組合產品。*列更新盡可能經常。

O

組學

1267件

公司參與了捕獲、測序和/或分析基因組、轉錄組、蛋白質組學和/或代謝組學數據

D

數字醫療

10530件

數字健康收藏品包括供應商開發軟件、平台、傳感器和機器人硬件,在醫療健康數據基礎設施和tech-enabled服務。列表中不包括製藥/生物製藥、測序儀器,基因編輯和輔助技術。

H

它的健康

7901件

W

女性健康科技

480件

良好的開端遺傳學專利

好的開始遺傳學提起了43個專利。

3最受歡迎的專利主題包括:

  • 遺傳學
  • 分子生物學
  • 生物技術
專利圖

申請日

授予日期

標題

相關的話題

狀態

8/30/2018

6/20/2023

常染色體隱性障礙、罕見疾病遺傳學、分子生物學、醫學遺傳學

格蘭特

申請日

8/30/2018

授予日期

6/20/2023

標題

相關的話題

常染色體隱性障礙、罕見疾病遺傳學、分子生物學、醫學遺傳學

狀態

格蘭特

最新的良好的開端遺傳學新聞

保障科學合作夥伴公司良好的開端遺傳學收購Invitae公司

2017年7月31日

17:15等分享這篇文章提供的消息,二。,July 31, 2017 /PRNewswire/ -- Safeguard Scientifics, Inc. (NYSE: SFE ) today announced that its partner company, Good Start Genetics, Inc. ("Good Start"), signed a definitive agreement to be acquired by San Francisco-based genetics information company, Invitae Corporation (NYSE: NVTA ). The transaction is expected to close in the first part of August 2017, subject to customary closing conditions. Safeguard expects to receive initial consideration consisting of $3.8 million of Invitae common stock, based on the 30-day trailing average stock price, and an additional $1.3 million of Invitae common stock which will be held in escrow for up to 13 months. Invitae is one of the fastest growing genetic information companies in the U.S. whose longer-term strategy is to aggregate most of the world's genetic tests into a single service with higher quality, faster turnaround time, and lower price than many single-gene and panel tests today. The company currently provides a diagnostic service comprising approximately 1,500 genes for a variety of genetic disorders associated with oncology, cardiology, neurology, pediatrics, and other rare disease areas, as well as clinical analysis of a 20,000-gene medical exome. Stephen T. Zarrilli, Safeguard's President and CEO, said, "From Safeguard's perspective, this outcome represents a significant shortfall based on our return expectations. However, considering the anticipated time and cost required to introduce additional technologies and tests into adjacent markets and to further develop Good Start, we believe that a larger, more financially capable enterprise that is focused on genetic testing was necessary to move Good Start's vision forward." "Good Start is an excellent strategic fit with Invitae," said Gary J. Kurtzman, MD, Managing Director at Safeguard and board member at Good Start. "We believe that Invitae is the best partner to advance the mission Good Start began seven years ago." About Safeguard Scientifics Safeguard Scientifics (NYSE: SFE ) provides capital and relevant expertise to fuel the growth of technology-driven businesses in healthcare, financial services and digital media. Safeguard targets companies that are capitalizing on the next wave of enabling technologies with a particular focus on the Internet of Everything, enhanced security and predictive analytics. Safeguard typically deploys between $5 million and $25 million over the course of its partnership with a company, initially investing in a Series A or B Round and opportunistically in a Seed Round. Safeguard has a distinguished track record of fostering innovation and building market leaders that spans more than six decades. For more information, please visit www.safeguard.com or follow us on Twitter @ safeguard . Forward-looking Statements Except for the historical information and discussions contained herein, statements contained in this release may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Our forward-looking statements are subject to risks and uncertainties. The risks and uncertainties that could cause actual results to differ materially include, among others, our ability to make good decisions about the deployment of capital, the fact that our partner companies may vary from period to period, our substantial capital requirements and absence of liquidity from our partner company holdings, fluctuations in the market prices of our publicly traded partner company holdings, competition, our inability to obtain maximum value for our partner company holdings, our ability to attract and retain qualified employees, market valuations in sectors in which our partner companies operate, our inability to control our partner companies, our need to manage our assets to avoid registration under the Investment Company Act of 1940, and risks associated with our partner companies, including the fact that most of our partner companies have a limited history and a history of operating losses, face intense competition and may never be profitable, the effect of economic conditions in the business sectors in which Safeguard's partner companies operate, and other uncertainties described in our filings with the Securities and Exchange Commission. Many of these factors are beyond the Company's ability to predict or control. As a result of these and other factors, the Company's past financial performance should not be relied on as an indication of future performance. The Company does not assume any obligation to update any forward-looking statements or other information contained in this press release. SAFEGUARD CONTACT: Senior Vice President, Investor Relations and Corporate Communications 610.975.4952

良好的開端遺傳學常見問題(FAQ)

  • 良好的開端遺傳學的總部在哪裏?

    良好的開端遺傳學的總部坐落在普特南大街237號,劍橋。

  • 良好的開端遺傳學的最新一輪融資是什麼?

    良好的開端遺傳學的最新一輪融資收購。

  • 良好的開端遺傳學籌集了多少錢?

    良好的開端遺傳學提出共60美元。

  • 良好的開端遺傳學的投資者是誰?

    投資者良好的開端遺傳學包括Invitae、環球化,維護科學,OrbiMed Advisors SV投資者和3更健康。

  • 良好的開端遺傳學的競爭對手是誰?

    良好的開端遺傳學的競爭對手包括Ativa醫療、AutoGenomics,牛津生物動力學,第三隻眼診斷,高潮生物科學和13。

188bet游戏
尋找一個腿上有競爭力的,客戶技術見解?
188bet游戏CB的見解將信心和清晰你最戰略決策。
看看。加入一個演示。
加入一個演示
信任由世界最聰明的公司:
  • 預測新興趨勢
  • 看到競爭對手的劇本
  • 莖精明的投資者
  • 確定明天的挑戰者
  • 現貨產業增長
  • 殺了分析師的數據工作
讓我們看看我們如何能幫助你!
微軟 沃爾瑪 富國銀行(Wells Fargo)

比較好的開始遺傳學和競爭對手

E
珠峰生物醫學

珠峰新生兒聽力篩查設備,結合目前市場誘發耳聲排放和聽覺腦幹反應。公司總部位於聖路易斯,密蘇裏州,並正在開發一個手持,電池監控裝置使anesthetician知道什麼是發生在整個大腦,而病人麻醉。

C
Cervimark

Cervimark醫療診斷公司,正在開發一個篩選試驗預測早產的高危妊娠。測試是基於量化生物標誌物發現懷孕的患者的分泌物和關聯結果數據早產的風險。概念驗證對於這個測試已經證明在一個很小的人體試驗。

一個
Ativa醫療

Ativa醫療是醫療診斷公司致力於提供診斷測試結果的時刻,而不是幾小時或幾天。

N
神經診斷設備

NeuroDx地址重要神經外科市場的未滿足的需求。ShuntCheck,他們的主要產品是一個援助的檢測offlow植入腦脊液(CSF)分流術。

m2m成像

Corp.m2m成像,在美國設有辦事處和澳大利亞生產的高清成像和工作流程解決方案生命科學應用MRI,寵物,CT和SPECT分析、臨床前和臨床研究環境。m2m的核磁共振線圈和附件包括產品組合,提供了解決方案,使在特定情況下的研究結果應用到世界各地。

E
表達診斷

新是一個分子診斷公司專注於發現、開發和商業化的非侵入性的基因表達檢測領域的移植醫學和自身免疫。每個公司,他們開發了一種專有的方法利用血液中基因表達,旨在為醫生提供一個新工具來管理心髒移植手術患者的護理。分子表達的新技術開發和實施正在探討心髒移植病人管理協助涉及免疫係統的其他疾病。

發現正確的解決方案為您的團隊

CB見解188bet游戏科技市場情報平台分析數百萬數據點在供應商、產品、合作關係,專利來幫助您的團隊發現他們的下一個技術解決方案。

加入一個演示

CBI的網站通常使用一些餅幹,使更好的相互作用我們的網站和服務。使用這些餅幹,這可能是存儲在你的設備上,允許我們的改進和定製你的經曆。你可以閱讀更多關於你的餅幹的選擇在我們的隱私政策在這裏。繼續使用這個你同意這些選擇。

Baidu
map